AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 242 min read$INSM

Lewis William sold $1.1M of INSM

Lewis William (Chair and CEO) sold 10,700 shares of INSMED Inc (INSM) at an average of $106.06 ($105.62–$106.43, $1.13M total) across 2 trades on 2026-07-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lewis William
Published Jul 24, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 24, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INSM
Neutral
high confidence
Mentioned
$INSM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

The disclosure updates the insider transaction record and may affect short-term sentiment, but it does not introduce new guidance, trial results, regulatory actions, or deal activity.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a fundamental repricing.

03

What to watch

Because the trades are under a 10b5-1 plan, the sale timing is mechanically scheduled and may not reflect current expectations.

Relevance 5/10Novelty 3/10Timing: Filed on 2026-07-24, covering sales executed on 2026-07-23.

Background

The article is a primary-source SEC Form 4 disclosure of an insider open-market sale by INSMED’s Chair and CEO, Lewis William, under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$INSMNeutralHigh confidence
Context

INSMED CEO and Chair Lewis William sold 10,700 shares in open-market trades at about $105.62 to $106.43 per share under a 10b5-1 plan.

Expected impact

Likely minimal, unless traders interpret the sale as a sentiment read-through.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

Sector

No sector read-through is provided beyond a single planned insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Some traders may still view a large CEO sale as a mild negative sentiment signal, especially if it coincides with other unreported concerns.

Key entities

  • issuer
    INSMED Inc

    Company whose shares were sold by its Chair and CEO under a 10b5-1 plan.

  • insider
    Lewis William

    Chair and CEO who executed the open-market sale(s) disclosed on Form 4.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INSM insider trading history →

Related articles

SEP 28
$INSMMedAI 8/10

Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?

Insmed (INSM) announced the FDA granted priority review for its ARIKAYCE lung drug, setting a January 2027 decision date. The application seeks full approval for broader use in treating MAC lung disease. Clinical trial results showed significant improvements in respiratory symptoms and bacterial conversion rates. Success could expand the patient pool and increase revenue, but regulatory, tolerability, and commercialization risks remain.

insidermonkey.com2 min
SEP 22
$INSMHighAI 8/10

FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce

Insmed (INSM) announced the FDA accepted its filing for Arikayce's label expansion to treat newly diagnosed MAC lung disease, with a decision expected by Jan. 28, 2027. The filing is supported by positive phase IIIb ENCORE study results. Arikayce sales grew 7% YoY to $214.4M in H1 2026, with full-year sales projected at $450M-$470M. The expansion could significantly increase Arikayce's market potential, according to the company.

zacks.com2 min
SEP 21
HighAI 8/10

Why is Insmed stock climbing today?

Insmed stock rose 2.0% in pre-market trading after the FDA accepted and granted Priority Review to its sNDA for ARIKAYCE, targeting a decision by January 28, 2027. The application seeks full approval for the drug, backed by Phase 3b ENCORE study results. Full approval would expand ARIKAYCE's use to newly diagnosed patients and those with recurrent infections. Insmed also plans to engage Japan's pharmaceutical regulator in Q4 2026 for potential label expansion.

investing.com2 min
SEP 21
$INSMHighAI 8/10

Insmed stock rises on FDA priority review for Arikayce

Insmed Inc. (NASDAQ:INSM) shares rose 2% premarket after the FDA granted priority review to its sNDA for Arikayce, targeting MAC lung disease. The FDA set a review deadline of January 28, 2027. Arikayce, approved in 2018, could see expanded use if the application succeeds. The sNDA is backed by Phase 3b ENCORE study results showing significant improvements in respiratory symptoms and culture conversion.

investing.com1 min